Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.
The developer of a drug for the rare multiple system atrophy, Alterity will launch a pivotal phase III trial after a go-ahead ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email [email protected]. MyChart is a ...
The cause of MSA remains unknown. Several lines of evidence suggest that inflammation could contribute to neurodegeneration in MSA. [9–11] Microglia are the primary immune effector cells in the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results